Special Issue

Nucleic Acid-based Drug

Message from the Guest Editor

RNA Therapeutics is an innovative strategy and a new molecular entity with the potential to to treat a wide variety of diseases. Research and development in oligonucleotide-based drugs have grown tremendously over the past decade. This Special Issue, "Nucleic Acid-based Drug", will cover different aspects of RNA drug discovery and development from chemical synthesis and modifications of antisense oligonucleotide (ASO), small interfering RNA (siRNA), anti-microRNA (anti-miRNA) and steric-blocking oligonucleotides, delivery systems to enhance cellular penetration, and preclinical and clinical studies of RNA therapeutics in the treatment of genetic diseases, cancers, metabolic diseases, cardiovascular diseases, lung diseases, wound healing, and infectious diseases.

Guest Editor

Prof. Dr. Wai Shiu Fred Wong

Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore 117600, Singapore

Deadline for manuscript submissions

closed (30 July 2016)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/6039

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

